IN2012DN02412A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02412A
IN2012DN02412A IN2412DEN2012A IN2012DN02412A IN 2012DN02412 A IN2012DN02412 A IN 2012DN02412A IN 2412DEN2012 A IN2412DEN2012 A IN 2412DEN2012A IN 2012DN02412 A IN2012DN02412 A IN 2012DN02412A
Authority
IN
India
Prior art keywords
therapeutic agent
dexanabinol
farnesyltransferase
cdk5
cdk2
Prior art date
Application number
Inventor
Malcolm Philip Young
Philip Mckeown
Original Assignee
Theraputics Plc E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraputics Plc E filed Critical Theraputics Plc E
Publication of IN2012DN02412A publication Critical patent/IN2012DN02412A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NFKB), Cyclin- dependent kinases, e.g. CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol, or a derivative thereof, as the therapeutic agent.
IN2412DEN2012 2009-09-10 2010-09-10 IN2012DN02412A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0915877.5A GB0915877D0 (en) 2009-09-10 2009-09-10 Cancer cell apoptosis
PCT/GB2010/001710 WO2011030106A1 (en) 2009-09-10 2010-09-10 Cancer cell apoptosis

Publications (1)

Publication Number Publication Date
IN2012DN02412A true IN2012DN02412A (en) 2015-08-21

Family

ID=41228122

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2412DEN2012 IN2012DN02412A (en) 2009-09-10 2010-09-10

Country Status (18)

Country Link
US (2) US20120190735A1 (en)
EP (1) EP2475364A1 (en)
JP (2) JP5930204B2 (en)
KR (1) KR20120090060A (en)
CN (2) CN102573833A (en)
AU (1) AU2010294055B2 (en)
BR (1) BR112012005262A2 (en)
CA (1) CA2771099A1 (en)
GB (1) GB0915877D0 (en)
IL (1) IL218008A (en)
IN (1) IN2012DN02412A (en)
MX (1) MX337433B (en)
MY (1) MY161186A (en)
NZ (1) NZ598652A (en)
RU (1) RU2592230C2 (en)
SG (1) SG178604A1 (en)
WO (1) WO2011030106A1 (en)
ZA (1) ZA201201981B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
GB0719771D0 (en) * 2007-10-10 2007-11-21 Therapeutics Ltd E Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma
GB0915877D0 (en) * 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
GB201207305D0 (en) * 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
CN116726181B (en) * 2023-08-09 2023-10-20 四川省医学科学院·四川省人民医院 Use of agent for inhibiting NAT9 gene expression

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3249109A (en) 1963-11-01 1966-05-03 Maeth Harry Topical dressing
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4262003A (en) 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
IL80411A (en) 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
IL115245A (en) 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
EP1002535A1 (en) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
CA2411585A1 (en) 2000-06-22 2001-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
CA2457011C (en) * 2001-08-20 2012-04-24 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes
CN100459982C (en) * 2004-08-30 2009-02-11 鲁南制药集团股份有限公司 Dispersible tablet form of doxifluridine
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
GB0915877D0 (en) * 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis

Also Published As

Publication number Publication date
AU2010294055A1 (en) 2012-04-05
US20120190735A1 (en) 2012-07-26
JP2013504550A (en) 2013-02-07
GB0915877D0 (en) 2009-10-14
MX337433B (en) 2016-03-04
RU2012113875A (en) 2013-10-20
NZ598652A (en) 2014-05-30
JP2015214579A (en) 2015-12-03
MX2012002992A (en) 2012-07-17
MY161186A (en) 2017-04-14
BR112012005262A2 (en) 2016-03-15
IL218008A (en) 2016-10-31
CN105935357A (en) 2016-09-14
RU2592230C2 (en) 2016-07-20
ZA201201981B (en) 2013-05-29
US20180042891A1 (en) 2018-02-15
KR20120090060A (en) 2012-08-16
EP2475364A1 (en) 2012-07-18
IL218008A0 (en) 2012-04-30
WO2011030106A1 (en) 2011-03-17
CN102573833A (en) 2012-07-11
JP5930204B2 (en) 2016-06-08
AU2010294055B2 (en) 2014-10-02
SG178604A1 (en) 2012-04-27
CA2771099A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
SG178604A1 (en) Cancer cell apoptosis
CL2007001434A1 (en) USE OF AN INTERFERENCE RNA OF THE CONVERTER ENZYME OF THE ALFA TUMOR NECROSIS FACTOR (TACE) TO TREAT TNF ALFA-RELATED DISEASES; AND COMPOSITION THAT UNDERSTANDS IT.
UY31360A1 (en) PERMEABILIZING PEPTIDES AND POLYPEPTIDES OF CELLS FOR MICROBIAL CELLS
CL2010001018A1 (en) An ultrasound transducer cartridge attached to a body to form a therapy head.
MX2015011583A (en) Amatoxin derivatives.
ECSP14001249A (en) IMMUNOBINDERS TARGETED AGAINST TNF
MX2013010286A (en) Amatoxin-conjugates with improved linkages.
CO6640205A2 (en) Microorganisms and methods for the biosynthesis of p-tolute and terephthalate
BR112013027553A2 (en) mevalonate, isoprene, and isoprenoid production using genes encoding polypeptides having thiolase, hmg-coa synthase and hmg-coa reductase enzymatic activities
MX2011006290A (en) Azaazulene compounds.
BR112012010614A2 (en) high intensity focused ultrasound curved transducer (hifu)
MY186824A (en) Glucosylceramide synthase inhibitors
GT201200271A (en) PROTEINS THAT JOIN TNF-A
EP4559918A3 (en) Glucosylceramide synthase inhibitors
EA201290901A1 (en) PHYTOCANNABINOIDS FOR THE TREATMENT OF MALIGNANT TUMOR
MX345155B (en) Combinations of a pi3k inhibitor and a mek inhibitor.
IL220386B (en) Preparations for the elimination of cancer tumors and their uses
BR112012032008A2 (en) s100a4 antibodies and therapeutic uses thereof
BR112014029346A2 (en) computer-implemented system and method for setting up a medical treatment plan
EP2464435A4 (en) Configurations and methods of generating low-pressure steam
EP3383276A4 (en) Medical instrument including high frequency ultrasound transducer array
BR112012010616A2 (en) curved high intensity focused ultrasound (hifu) transducer
ES2570990T3 (en) Fermented food containing bifidobacterium bacteria and method to produce it
GT200800182A (en) TETRAHYDRONAFTALINE DERIVATIVES, PROCEDURES TO PREPARE THEM AND THEIR USE AS ANTI-INFLAMMATORIES
BR112012010628A2 (en) curved high intensity focused ultrasound (hifu) transducer